Phase 2 Study of the Response and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME)
- Resource Type
- Abstract
- Source
- In
Blood 13 November 2019 134 Supplement 1:3184-3184 - Subject
- Language
- ISSN
- 0006-4971